基本信息
浏览量:40
职业迁徙
个人简介
Research Abstract
1. Develop more effective therapies for hepatocellular carcinoma and cholangiocarcinoma through phase I, II and III clinical trials.
2. Identify novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance.
3. Define and characterize known or novel genetic mutations in hepatocellular carcinoma and cholangiocarcinoma, and assess their potential correlation with clinical outcomes and as therapeutic targets.
4. Dissect the molecular mechanism of drug resistance to targeted therapy in hepatobiliary cancers.
1. Develop more effective therapies for hepatocellular carcinoma and cholangiocarcinoma through phase I, II and III clinical trials.
2. Identify novel circulating and imaging biomarkers for targeted therapeutics that have prognostic and/or predictive significance.
3. Define and characterize known or novel genetic mutations in hepatocellular carcinoma and cholangiocarcinoma, and assess their potential correlation with clinical outcomes and as therapeutic targets.
4. Dissect the molecular mechanism of drug resistance to targeted therapy in hepatobiliary cancers.
研究兴趣
论文共 678 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Bin Fan,Ghassan K. Abou-Alfa,Andrew X. Zhu,Shuchi S. Pandya, Hongxia Jia,Feng Yin,Camelia Gliser, Zhaowei Hua,Mohammad Hossain,Hua Yang
Cancer Chemotherapy and Pharmacologypp.1-9, (2024)
Cancer cellno. 2 (2024): 180-197
Liver Cancer (2024)
JAMA oncologyno. 12 (2023): 1651-1659
Laura A. Dawson,Kathryn A. Winter,Jennifer J. Knox,Andrew X. Zhu,Sunil Krishnan, Chandan Guha,Lisa A. Kachnic,Michael Gillin,Theodore S. Hong, Timothy Craig,Ali Hosni,Eric Xueyu Chen,
ONCOLOGIST (2023)
Journal of Hepatology (2023): S574-S574
引用0浏览0引用
0
0
JAMA Oncology (2023)
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn